Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).
Saved in:
| Title: | Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial). |
|---|---|
| Authors: | Alshatti N; Gustave Roussy, Department of Therapeutic Innovation and Early Clinical Trials (DITEP), Université Paris-Saclay, Villejuif, France.; Institut National de la Santé et de la Recherche Médicale (INSERM) U1015 & CIC1428, Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), Villejuif, France., Lemonnier F; AP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Service Unité Hémopathies Lymphoïdes, Créteil, France.; Université Paris Est Créteil, INSERM, IMRB, Créteil, France., Bachy E; Hematology Department, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France.; Lymphoma Immuno-Biology (LIB) Research Unit, INSERM U1111, CIRI, Lyon, France., Lopez J; Biochemistry and Molecular Biology Department, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France., Llamas F; Service d'anatomie et cytologie pathologiques du CHU de Rennes, Rennes, France., Damotte D; Université Paris cité, APHP, Centre de Recherche des Cordeliers, INSERM U1138, Université de paris et Sorbonne université, Paris, France., Burroni B; Department of Pathology, Cochin Hospital, AP-HP. Centre, Université Paris Cité, Paris, France.; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Institut du cancer Paris CARPEM, Team Inflammation, Complement and Cancer, Paris, France., Velut Y; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Institut du cancer Paris CARPEM, Team Inflammation, Complement and Cancer, Paris, France., Mauduit C; Institut National de la Santé et de la Recherche Médicale, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France., de Charette M; Centre hospitalier universitaire de La Réunion, Saint-Paul, France., Roussel M; Unité Mixte de Recherche UMR1236, Institut National de la Santé et de la Recherche Médicale, INSERM, Université Rennes 1, Etablissement Français du Sang Bretagne, Equipe labellisée Ligue, LabEx IGO, Rennes, France.; Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, Rennes, France., Palard X; Université Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, Rennes, France., Marabelle A; Gustave Roussy, Department of Therapeutic Innovation and Early Clinical Trials (DITEP), Université Paris-Saclay, Villejuif, France.; Institut National de la Santé et de la Recherche Médicale (INSERM) U1015 & CIC1428, Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), Villejuif, France., Houot R; Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, Rennes, France. |
| Source: | Immuno-oncology technology [Immunooncol Technol] 2025 Oct 10; Vol. 29, pp. 101077. Date of Electronic Publication: 2025 Oct 10 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 9918281581106676 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-0188 (Electronic) Linking ISSN: 25900188 NLM ISO Abbreviation: Immunooncol Technol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41502913 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Alshatti+N%22">Alshatti N</searchLink>; Gustave Roussy, Department of Therapeutic Innovation and Early Clinical Trials (DITEP), Université Paris-Saclay, Villejuif, France.; Institut National de la Santé et de la Recherche Médicale (INSERM) U1015 & CIC1428, Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Lemonnier+F%22">Lemonnier F</searchLink>; AP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Service Unité Hémopathies Lymphoïdes, Créteil, France.; Université Paris Est Créteil, INSERM, IMRB, Créteil, France.<br /><searchLink fieldCode="AU" term="%22Bachy+E%22">Bachy E</searchLink>; Hematology Department, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France.; Lymphoma Immuno-Biology (LIB) Research Unit, INSERM U1111, CIRI, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Lopez+J%22">Lopez J</searchLink>; Biochemistry and Molecular Biology Department, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Llamas+F%22">Llamas F</searchLink>; Service d'anatomie et cytologie pathologiques du CHU de Rennes, Rennes, France.<br /><searchLink fieldCode="AU" term="%22Damotte+D%22">Damotte D</searchLink>; Université Paris cité, APHP, Centre de Recherche des Cordeliers, INSERM U1138, Université de paris et Sorbonne université, Paris, France.<br /><searchLink fieldCode="AU" term="%22Burroni+B%22">Burroni B</searchLink>; Department of Pathology, Cochin Hospital, AP-HP. Centre, Université Paris Cité, Paris, France.; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Institut du cancer Paris CARPEM, Team Inflammation, Complement and Cancer, Paris, France.<br /><searchLink fieldCode="AU" term="%22Velut+Y%22">Velut Y</searchLink>; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Institut du cancer Paris CARPEM, Team Inflammation, Complement and Cancer, Paris, France.<br /><searchLink fieldCode="AU" term="%22Mauduit+C%22">Mauduit C</searchLink>; Institut National de la Santé et de la Recherche Médicale, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.<br /><searchLink fieldCode="AU" term="%22de+Charette+M%22">de Charette M</searchLink>; Centre hospitalier universitaire de La Réunion, Saint-Paul, France.<br /><searchLink fieldCode="AU" term="%22Roussel+M%22">Roussel M</searchLink>; Unité Mixte de Recherche UMR1236, Institut National de la Santé et de la Recherche Médicale, INSERM, Université Rennes 1, Etablissement Français du Sang Bretagne, Equipe labellisée Ligue, LabEx IGO, Rennes, France.; Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, Rennes, France.<br /><searchLink fieldCode="AU" term="%22Palard+X%22">Palard X</searchLink>; Université Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, Rennes, France.<br /><searchLink fieldCode="AU" term="%22Marabelle+A%22">Marabelle A</searchLink>; Gustave Roussy, Department of Therapeutic Innovation and Early Clinical Trials (DITEP), Université Paris-Saclay, Villejuif, France.; Institut National de la Santé et de la Recherche Médicale (INSERM) U1015 & CIC1428, Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Houot+R%22">Houot R</searchLink>; Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, Rennes, France. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229918281581106676%22">Immuno-oncology technology</searchLink> [Immunooncol Technol] 2025 Oct 10; Vol. 29, pp. 101077. <i>Date of Electronic Publication: </i>2025 Oct 10 (<i>Print Publication: </i>2026). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9918281581106676 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2590-0188 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225900188%22">25900188 </searchLink><i>NLM ISO Abbreviation: </i>Immunooncol Technol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41502913 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.iotech.2025.101077 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 101077 Titles: – TitleFull: Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Alshatti N – PersonEntity: Name: NameFull: Lemonnier F – PersonEntity: Name: NameFull: Bachy E – PersonEntity: Name: NameFull: Lopez J – PersonEntity: Name: NameFull: Llamas F – PersonEntity: Name: NameFull: Damotte D – PersonEntity: Name: NameFull: Burroni B – PersonEntity: Name: NameFull: Velut Y – PersonEntity: Name: NameFull: Mauduit C – PersonEntity: Name: NameFull: de Charette M – PersonEntity: Name: NameFull: Roussel M – PersonEntity: Name: NameFull: Palard X – PersonEntity: Name: NameFull: Marabelle A – PersonEntity: Name: NameFull: Houot R IsPartOfRelationships: – BibEntity: Dates: – D: 10 M: 10 Text: 2025 Oct 10 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2590-0188 Numbering: – Type: volume Value: 29 Titles: – TitleFull: Immuno-oncology technology Type: main |
| ResultId | 1 |
